Alternative Routes of Administration of Clozapine Siobhan GeeDavid Taylor Current Opinion 03 February 2022 Pages: 105 - 111
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? Meir BialerEmilio Perucca Leading Article 30 January 2022 Pages: 113 - 122
Potential Role of Curcumin for the Treatment of Major Depressive Disorder Adrian L. Lopresti Leading Article Open access 07 February 2022 Pages: 123 - 141
Pharmacological Management of Apathy in Dementia Laiba AzharRaphael W. KusumoNathan Herrmann Review Article 10 January 2022 Pages: 143 - 165
Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies Lauren ChiecPriya Kumthekar Review Article 25 January 2022 Pages: 167 - 179
Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model Drew MacCannellZdenek BergerFrancesco Muntoni Original Research Article Open access 26 January 2022 Pages: 181 - 190
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score Luigi Francesco IannoneDavide FattoriFrancesco De Cesaris Original Research Article Open access 11 February 2022 Pages: 191 - 202
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“ Marco PappagalloCharles E. InturrisiPaolo L. Manfredi Letter to the Editor Open access 11 January 2022 Pages: 203 - 204
Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status” Ioline D. HenterLawrence T. ParkCarlos A. Zarate Jr. Letter to the Editor 11 January 2022 Pages: 205 - 206